MétaCan
Menu
Back to cohort

Abstract B049: Lipid nanoparticle-delivered toll-like receptor agonists are highly effective in cancer immunotherapy

2023· article· en· W4389240480 on OpenAlexaboutno aff
Jun Bai, Fei Su, Chen Li, Yujing Wu, Jing Li, Xiaobin Zhao, Yongsheng Yang

Bibliographic record

VenueCancer Immunology Research · 2023
Typearticle
Languageen
FieldEngineering
TopicNanoplatforms for cancer theranostics
Canadian institutionsnot available
Fundersnot available
KeywordsImmunotherapyMedicineTumor microenvironmentCancerImmune systemMelanomaCpG OligodeoxynucleotideCancer immunotherapyCancer researchCpG siteDosingImmunologyPharmacologyInternal medicineChemistry

Abstract

fetched live from OpenAlex

Abstract Background: Tumor immunotherapy has shown promising efficacy in various types of cancer. However, the effectiveness of immunotherapy is often limited by the immune-suppressive microenvironment within tumors. To address this challenge, we developed a method of intratumoral injection using lipid nanoparticles (LNPs) to deliver Toll-like receptor 7, 8, and 9 agonists. LNPs effectively enhance immune activation while reducing systemic responses by increasing drug retention within the tumor. Methods: We encapsulated 30nt-CpG and Resiquimod into LNPs (QTsomeTM). Subcutaneous inoculation of 2 × 106 MC38 cells was performed in mice. Once the average tumor volume reached approximately 100mm3, we divided 15 mice into 3 groups based on tumor volume. Intratumoral injections began on the same day of grouping, with a dosage of 1mg/kg (5 injections every 3 days). Tumor volume and body weight were measured twice a week. We conducted two parallel experiments, each with 7 mice for the MC38 model and 8 mice for the B16 melanoma model in each group, to compare the efficacy of 26nt-CpG and 30nt-CpG. Results: On the 15th day post-dosing, the tumor growth inhibition rate (TGI) was 79.9% (P<0.001), resulting in a 73.7% increase in survival rate. LNP-delivered 26nt-CpG demonstrated a TGI rate of 75.4% (P<0.001), while 30nt-CpG showed a TGI of 81.9% (P<0.001). Interestingly, the 26nt-CpG group exhibited faster weight gain, indicating better safety. In the mouse B16 melanoma model, LNP-delivered 26nt-CpG achieved a TGI rate of 75.2% (P<0.001), slightly higher than 30nt-CpG (71.0%, P<0.001), and also resulted in faster weight gain. Conclusion: In conclusion, the use of LNP-delivered Toll-like receptor agonists demonstrated excellent tumor therapeutic effects and good safety in mouse models. Activation of Toll-like receptors effectively stimulated immune cells such as CD8+ T cells and NK cells, enhancing their ability to kill tumor cells. Direct injection of LNPs into the tumor improved this effect while reducing systemic side effects. This drug holds promise as a broad-spectrum anti-tumor treatment and may have potential for expanding the indications of existing tumor immunotherapies. Citation Format: Jun Bai, Fei Su, Chen Li, Yujing Wu, Jing Li, Xiaobin Zhao, Yongsheng Yang, Robert J Lee. Lipid nanoparticle-delivered toll-like receptor agonists are highly effective in cancer immunotherapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2023 Oct 1-4; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2023;11(12 Suppl):Abstract nr B049.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.038
GPT teacher head0.337
Teacher spread0.299 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueCancer Immunology ResearchSame topicNanoplatforms for cancer theranosticsFrench-language works237,207